CYBB and Alzheimer disease: Furthermore, inhibiting or deleting Nox2 decreases inflammation‐elicited neuronal production of ROS in vitro[19] while deleting or inhibiting Nox2 reduces Aβ‐induced microglial production of ROS and IL‐1β in vitro.[21] These observations suggest that a pan‐Nox inhibitor such as CBR‐2131 may have better potential as a treatment for AD than more specific Nox inhibitors.